Calendario

Noviembre 2017
LunMarMierJueVierSabDom
 << < > >>
   1234
567891011
12131415161718
19202122232425
2627282930  

Anuncio

¿Quién está en línea?

Miembro: 0
Visitante: 1

rss Sindicación

Avr022015

17:40:34

Health Care Sector Update For 04/01/2015: Imdz,dyax,ctso - Nasdaq.com











( IMDZ ) was sharply higher Wednesday, with shares of the immunotherapy company rising after it reported positive top-line data from three Phase I tests of its immuno-oncology agents, supporting continued development of its CMB305 and G100 drug candidates. According to the company, both the "prime" LV305 component and the "boost" G305 component of CMB305 were well tolerated and demonstrated specific and selective immunogenicity during a pair of Phase I. "The data from the dose escalation Phase 1 studies of LV305 and G305 met our internal requirements for demonstrating that each of these two 'building blocks' of CMB305 selectively activates different arms of the immune response against NY-ESO-1," CEO Carlos Paya said in prepared remarks. The company last night also said it generated around $1.8 million in revenue during the final three months of 2014, up from no revenue during the same period last year. It also finished the year with $75.4 million in cash and equivalents, up 148% over the prior year period. IMDZ shares were up almost 26% at $26.50 in afternoon trade, earlier topping out at $27.37 a share. The stock has traded between $11.52 to $40.13 a share since pricing its initial public offering of stock last July 24, already rising more than 75% over that span prior to Wednesday's advance. In other sector news, (+) DYAX, (+48.3%) Reports positive results from early testing of the company's experimental angioedema drug. DX-2930 was found to have eliminated all attacks of hereditary angioedema when patients received 300 milligram doses while patient who got 400 milligrams saw an 88% drop in attacks.
Health Care Sector Update for 04/01/2015: IMDZ,DYAX,CTSO - NASDAQ.com







see here

Health Care Sector Update for 04/01/2015: TRVN,DYAX,CTSO - NASDAQ.com






The stock has traded within a 52-week range of $3.80 to $8.16 a share, slipping nearly 11% over the past year prior to today's rally. In other sector news, (+) DYAX, Reports positive early-stage result for its experimental angioedema drug, eliminating all attacks of hereditary angioedema in patients receiving 300 milligram doses. Patients in 400-milligram arm saw an 88% drop in attacks. (-) CTSO, FY14 net loss widens to $4.1 mln, or $1.29 per share, compared with $1.9 loss last year. It had no revenue last year, as expected. It expects Q1 revenue of $700,000 to $725,000, trailing analyst estimates by at least $149,000.
Health Care Sector Update for 04/01/2015: TRVN,DYAX,CTSO - NASDAQ.com




Admin · 284 vistas · Escribir un comentario

Vínculo permanente hacia el artículo completo

http://jacobwagomez.hazblog.com/Blog-b1/Health-Care-Sector-Update-For-04-01-2015-Imdzdyaxctso-Nasdaqcom-b1-p50.htm

Comentarios

Este artículo no tiene Comentario por el momento .....


Escribir un comentario

Estatuto de los nuevos comentarios: Publicado





Se mostrará tu URL


Por favor introduce el código contenido en las imágenes.


Texto del comentario

Opciones
   (Salvar el nombre, el mail y la URL en los cookies)